How Common SOFA and Ventilator Time Trial Criteria Would Have Performed During the COVID-19 Pandemic: An Observational Simulated Cohort Study

B. Corbett Walsh MD, MBE1, Deepak Pradhan MD1,2,3, Vikramjit Mukherjee MD1,3, Amit Uppal MD1,3, Mark E. Nunnally MD2,4 and Kenneth A. Berkowitz MD1,5,6

1Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA; 2New York University Langone Health, New York, NY, USA; 3Bellevue Hospital Center, NYC Health & Hospitals, New York, NY, USA; 4Department of Anesthesiology, Perioperative Care, and Pain Medicine, New York University Grossman School of Medicine, New York, NY, USA; 5National Center for Ethics in Health Care, Veterans Health Administration, Washington, DC, USA and 6Department of Population Health, New York University Grossman School of Medicine, New York, NY, USA

Abstract

Objectives: To evaluate how key aspects of New York State Ventilator Allocation Guidelines (NYSVAG)—Sequential Organ Failure Assessment score criteria and ventilator time trial criteria—might perform with respect to the frequency of ventilator reallocation and survival to hospital discharge in a simulated cohort of coronavirus disease (COVID-19) patients.

Methods: Single center retrospective observational and simulation cohort study of 884 critically ill COVID-19 patients undergoing ventilator allocation per NYSVAG.

Results: In total, 742 patients (83.9%) would have had their ventilator reallocated during the 11-day observation period, 280 (37.7%) of whom would have otherwise survived to hospital discharge if provided with a ventilator. Only 65 (18.1%) of the observed surviving patients would have survived by NYSVAG. Extending ventilator time trials from 2 to 5 days resulted in a 49.2% increase in simulated survival to discharge.

Conclusions: In the setting of a protracted respiratory pandemic, implementation of NYSVAG or similar protocols could lead to a high degree of ventilator reallocation, including withdrawal from patients who might otherwise survive. Longer ventilator time trials might lead to improved survival for COVID-19 patients given their protracted respiratory failure. Further studies are needed to understand the survival of patients receiving reallocated ventilators to determine whether implementation of NYSVAG would improve overall survival.

By the time the World Health Organization (WHO) declared coronavirus disease (COVID-19) a pandemic on March 11, 2020, 113 countries had confirmed cases, with 80,955 cases reported in China and 696 in the United States. By the end of that month, 5% of all worldwide cases and 1 in 3 of US cases and deaths were in New York City. This created a real concern that hospitals might suffer a shortfall of resources and need to ration ventilators. Developed in 2007 and updated in 2015 to address such a scenario, the New York State Department of Health along with New York State Task Force on Life and the Law released the New York State Ventilator Allocation Guidelines (NYSVAG). This document draws upon a community’s duty to care, resource stewardship, transparency, and distributive justice to save the most lives. Briefly, this unvalidated strategy heavily utilizes the Sequential Organ Failure Assessment (SOFA), a summative 0-24 score of organ dysfunction across neurologic, pulmonary, cardiovascular, hematologic, hepatobiliary, and renal domains, to prioritize (colored red for highest or yellow for intermediate) and potentially exclude patients from a ventilator (colored blue). Patients triaged and provided a ventilator receive 1 for a pre-specified duration of time. After the ventilator time trial, their SOFA scores are recalculated, and patients are re-triaged to maintain their ventilators or have them reallocated to other patients. NYSVAG are very similar to other available crisis standard of care guidelines, 205.6% of which utilize a SOFA score. Moreover, and similar to NYSVAG, 35.6% exclude patients from a ventilator for a SOFA score > 11, and 65.5% use the same ventilator time trial intervals (2 days, 5 days, and every subsequent 2 days). With only 1 documented case of ventilator rationing by NYSVAG exclusionary criteria in New York City during the original surge, and with Alaska and Idaho having both activated regional crisis standards of care that explicitly permit ventilator rationing (Alaska uses verbatim SOFA cutoffs as NYSVAG and Idaho use a similar SOFA and time trial criteria as NYSVAG), it remains crucial to understand how these guidelines might perform.
Table 1. New York State ventilaotr allocation guidelines steps 2 and 310

| Ventilator color triage                          | Step 2 intubation assessment | Step 3 Day 2 reassessment | Step 3 Day 5 reassessment | Every subsequent 2 day reassessment |
|-------------------------------------------------|------------------------------|---------------------------|---------------------------|-----------------------------------|
| Blue Ineligible for a ventilator                | SOFA > 11                    | SOFA > 11 and no change in SOFA compared to prior assessment | SOFA > 7 with no change in SOFA compared to prior assessment | SOFA > 7 with no change in SOFA compared to prior assessment |
| Red Ventilator provided or maintained with highest priority | SOFA ≤ 7                      | SOFA ≤ 11 and decrease in SOFA compared to prior assessment | SOFA ≤ 7 and progressive decrease in SOFA compared to prior assessment (≥ 3) | SOFA ≤ 7 with decrease in SOFA compared to prior assessment |
| Yellow Ventilator provided or maintained with intermediate priority | SOFA 8-11                    | SOFA ≤ 7 and no change in SOFA compared to prior assessment | SOFA ≤ 7 and minimal decrease in SOFA compared to prior assessment (< 3) | SOFA ≤ 7 with decrease in SOFA compared to prior assessment |

Three gaps in NYSVAG that were addressed as follows: (1) Patients with a SOFA score of 7 on the day of intubation were categorized as Red; (2) Individuals with a SOFA score greater than 7 on any assessment after 5 days of mechanical ventilation were ineligible for a ventilator; and (3) Patients ventilated for 7 or more days who continued to show a SOFA score ≥ 7 and decreasing were placed in the Yellow category.

Objectives

It remains uncertain how such ventilator allocation guidelines would perform if implemented. This study simulates how specific SOFA cutoffs for resource prioritization and the ventilator time trials, used in NYSVAG and other crisis standards of care documents, might affect ventilator allocation and patient survival in a COVID-19 cohort during the pandemic. To address this research question, the relevant portions NYSVAG were simulated on every patient independently to one another and independent to the number of available ventilators, thereby aligning temporally discordant patient hospitalizations. This design can reveal important guideline inefficiencies that might potentiate mortality and remain obscure when incorporating a fixed ventilator supply with variable or low ventilator strain. Moreover, this analysis is helpful to evaluate how explicit triage criteria (SOFA cutoffs and ventilator time trials) would perform in an isolated manner that is independent to the resources available at a facility. Such an evaluation can determine whether a resource allocation strategy may be effective given the trajectory of patient survival or whether it might reallocate resources away from patients who would otherwise survive. Additionally, a retrospective analysis where each patient received a ventilator provides a unique control group to simulate resource allocation protocols because their survival with a ventilator is known. The results of this analysis remain germane to developing efficient crisis standard of care procedures and could provide reassurance of existing ventilator allocation guidelines or suggest the need for further revisions.

Methods

Adult patient charts were retrospectively reviewed from a single academic hospital system encompassing 1 tertiary care referral center and 2 community hospitals from 3/1/2020–7/1/2020. Patients were included if they were SARS-CoV-2 positive and were invasively mechanically ventilated. Components of the SOFA score were obtained for each patient daily as close to 10:00 AM as possible. Missing components of the SOFA score were presumed normal.19,20 If there was no reported SOFA score on the day of intubation, the SOFA score from the next day was used instead for the day of intubation (and for relevant comparisons). Every patient received a ventilator as medically indicated, and ventilator allocation or reallocation per NYSVAG only occurred in a virtual simulation.

NYSVAG were interpreted for this study in the following manner: Step 1, the application of exclusionary criteria, was deferred because the number of such patients was negligible (Supplement Figure 1).20 Steps 2 and 3, the allocation and potential reallocation of ventilators respectively, were simulated on each patient as described in NYSVAG (Table 1; Supplement Figures 2, 3a-b). Patients categorized as Red received the highest priority for a ventilator, followed by those patients classified as Yellow. Patients classified as Blue were ineligible for a ventilator.

NYSVAG were applied to the cohort in the following simulation (see Supplemental Methods for additional details): Every patient's SOFA score was calculated on the day of intubation, Day 2 of mechanical ventilation, Day 5, and every subsequent 2 days of mechanical ventilation. Any patient who was characterized as Red or Yellow would receive (or maintain) a ventilator; however, any patient characterized as Blue would have her or his ventilator withheld (or reallocated) on the day that patient was characterized as ineligible for a ventilator. This design was chosen because this analysis can evaluate a central component of the guidelines (SOFA score cutoffs and ventilator time trials) independent to the number of available ventilators, patient throughput, ventilator strain, or impact from randomization. Patients who had their ventilator withheld or reallocated were simulated to expire as modeled in other simulation studies withholding or withdrawing life-sustaining treatment.21,22 Patients were also removed from the simulation if they expired, were extubated, or placed on extracorporeal membrane oxygenation (ECMO) between assessment days.

Outcome measurements include both observed (what occurred in the real world) and simulated (what occurred hypothetically) endpoints. Because every patient in our cohort received a ventilator in the real world, their performance with respect to survival to hospital discharge with continued ventilation is known (referenced as an observed outcome). The primary observed endpoints include death or survival to discharge. The primary simulated endpoints...
include whether the patient’s ventilator was simulated to be withheld or reallocated on the day of intubation, 2, 5, 7, 9, or 11 days post-intubation (Figure 1). Combined simulated-observed endpoints include whether the patient had her or his ventilator reallocated (simulated) but was observed to survive to hospital discharge (observed, how the patient would have performed if provided with a ventilator). Comorbidities were queried from the ICD-10 problem list.

Missing data were amended in 2 subsequent simulations. First, all Glasgow Coma Scale (GCS) SOFA subscores were normalized (GCS-nl). Second, missing pulmonary SOFA subscores were supplemented by the modified SOFA pulmonary category (mSOFA-FiO2). As oxygen saturation was not gathered and FiO2 was, pulmonary mSOFA scores were computed with a presumptive oxygen saturation of 85% or better. A fourth simulation delayed the Day 2 reassessment to Day 5, the Day 5 reassessment to Day 7, and the subsequent 2-day reassessments to start on Day 9 (MVD 2to5).

Categorical data were analyzed with the chi-square test using the 95% confidence interval (CI). Continuous variables were compared with a 2-tailed t-test using a 5% significance level.

This study was approved by the NYU Grossman School of Medicine Institutional Review Board (study #i20-01653). No treatment, ventilator allocation, or reallocation decisions were made for any patient. Patients were exempt from informed consent.

Results

Observed Results

COVID-19 patients, 884 in total, were intubated between 3/1/2020 and 7/1/2020 and included in the simulation. The average age of the cohort was 63 years, predominately male (70.0%), with varied racial ethnicities (Table 2). Comorbidity information was only available for 50% the cohort (Supplement Table 1). The median (IQR) duration of mechanical ventilation for the cohort was 10.2 (3.74, 23.73) days, with 41.0% survival to discharge.

Simulation Results

NYSVAG were applied to the observed patient SOFA scores in a simulation shown in Figure 2 and Table 3. Table 4 depicts how simulated patients, on each day of reassessment, were triaged as ineligible to receive or maintain a ventilator (Blue) and how many were observed to survive to discharge.

Step 2: Assessment at intubation

In total, 884 patients underwent Step 2 of NYSVAG—prioritization and allocation of a ventilator. Average SOFA on the day of triage for mechanical ventilation was 7.4 ± 3.3; 478 (54.1%) individuals qualified as Red, the highest priority for a ventilator, 285 (32.2%) as Yellow or intermediate priority for a ventilator, and 121 (13.7%) as Blue or ineligible for a ventilator. Of the 121 individuals triaged as Blue and not provided with a ventilator in the simulation, 31 (25.6%) were observed to survive to discharge. Of the 763 patients who were initially prioritized to receive a ventilator (Red or Yellow), 249 (32.6%) would later be triaged in the simulation to have their ventilator reallocated (Blue) but would have otherwise been observed to survive to discharge (observed outcome).

Step 3: Day two reassessment

From the day of intubation to 2 days post-intubation, 41 individuals had expired, 35 had been extubated, and 10 had been placed onto ECMO. As such, 678 patients were reassessed on post-intubation Day 2. Of this group, 223 (32.9%) were characterized as Red and 50 (7.4%) as Yellow. Per NYSVAG, for those being reassessed after 2 days of mechanical ventilation, 404 individuals (59.7%) would have had their ventilator reallocated, 136 (20.4%) as Red, 204 (30.5%) as Blue, and 121 (17.7%) as Yellow.

Table 4 describes how many simulated patients, on each day of reassessment, were triaged as ineligible to receive or maintain a ventilator (Blue) and how many were observed to survive to discharge.
Individuals characterized as Blue with a worsening SOFA score less than 7 were also more likely to survive to hospital discharge with a ventilator than those with a SOFA score of 8-11 ($P = 0.04$).

**Step 3: Day five reassessment**

Of the 678 patients from Day 2, 24 individuals were extubated, 16 expired, and 7 were placed onto ECMO, and 405 were extubated due to the ventilator reallocation that occurred because of the Day 2 reassessment. As such, 226 patients were present to be reassessed after 5 days of mechanical ventilation. At this time, 25 individuals (11.1%) were triaged as Red and 39 (17.3%) as Yellow; 162 patients (71.7%) were triaged as Blue and were simulated to have their ventilator reallocated, 75 (46.3%) of whom were observed to survive to discharge. Among these 162 individuals, both the 88 individuals (54.3% of all reassessed as Blue, 55.7% observed survival) who had a worsening SOFA score less than 7 and the 61 individuals (37.7%, 41.0% survival) who had a SOFA score of 8-11 were more statistically likely to be discharged alive if provided with a ventilator than those 13 individuals (8.0%, 7.7% survival) who had a SOFA score greater than 11 ($P = 0.001$ and $P = 0.02$, respectively).

**Step 3: Day seven reassessment**

Of the 226 patients from Day 5, 5 individuals were extubated, 3 expired, and 162 were extubated due to the ventilator reallocation on the Day 5 Reassessment. As such, 56 patients were present to be reassessed after 7 days of mechanical ventilation. At this time, 7 individuals were prioritized for a ventilator. 49 patients (87.5%) received the reallocated ventilators, 34 (69.4%) of whom were observed to survive to discharge. Amongst these 49 individuals, the 42 individuals (85.7% of all reassessed as Blue, 78.6% observed survival) who had a worsening SOFA score less than 7 were more statistically likely to be discharged alive if provided with a ventilator than and the 7 individuals (14.3%, 14.3% survival) who had a SOFA score of 8-11 ($P < 0.001$).

After 11 days of simulation, all 884 patients would have either been extubated and survived to hospital discharge, expired, had their ventilator reallocated, or placed onto ECMO; 742 patients would have had their ventilator reallocated (83.9% of the original cohort), 280 (37.7%) of whom were observed to survive to discharge if provided with a ventilator. Of the total 360 patients observed to survive to discharge, only 65 (18.1%) would have survived to discharge without having their ventilator reallocated in the simulation. There was no statistically significant ventilator reallocation by age, gender, race, or ethnicity at any day of assessment, among all who had their ventilator reallocated, or among those who were simulated to survive.

**Missing data and additional analyses**

Our cohort required 1852 patient-SOFA-days (a SOFA score for each day a ventilated patient was assessed). The majority of missing information was on the day of intubation, with 100 patients having no SOFA score on the day of intubation (Supplement Table 2). Additional modeling with adjusted or supplemented SOFA scores, as well as deferring NYSVAG Day 2 reassessment to Day 5, is shown in Figure 3. We failed to find a significant difference in simulated surviving individuals when normalizing the GCS or supplementing pulmonary SOFA sub-scores (72 GCS-nl versus 65; see Figure 3). A delay in the Day 2 reassessment to Day 5 (MVD 2to5) resulted in a 49.2% increase in simulated survival to discharge within NYSVAG criteria.

**Discussion**

Our findings simulate the performance of common triage criteria (SOFA cutoffs and ventilator time trials) on a large cohort of critically ill COVID-19 patients. Ventilator reallocation was simulated to occur for 83.9% (742/884) of the cohort, 37.7% (280/742) of whom would have survived to discharge if provided with a ventilator. Additionally, only 18% (65/362) of all individuals who were observed to survive to discharge were also simulated to survive to discharge within the simulated NYSVAG criteria. This raises a significant concern that under this ventilator allocation protocol, ventilators might be taken away from patients who would otherwise survive. This concern would be assuaged if the subsequent patients who received the reallocated ventilators would have fared much better, thereby improving overall group survival. This would satisfy the NYSVAG utilitarian goal of doing the most good for the most people, commonly interpreted as saving the most lives.10

Others have articulated that any redistribution of lifesaving resources must be fair, transparent, and promote equity among vulnerable and marginalized populations.23-26 It is therefore encouraging that any ventilator distribution per NYSVAG was not statistically significant among any age, gender, ethnic, or racial groups.

Our results contrast with that reported by Wunsch et al., a similar retrospective simulation of applying NYSVAG to 40,439 intubated critically ill patients from 2014-2015.20 Our cohort of COVID-19 patients was sicker than their mixed medical/surgical population (initial COVID-19 SOFA of 7.4 ± 3.3 compared to 4.5 ± 3.7), which may account for the larger proportion triaged as ineligible for a ventilator (Blue, 13.7% vs 8.9%). On the second or fifth reassessment day, only 4.7% or 28.3% of their cohort was classified as ineligible for a ventilator (Blue), respectively. This contrasts concerningly to the 59.7% and 71.7% simulated in our cohort of COVID-19 patients. Moreover, their median (IQR) duration of mechanical ventilation was 1.94 (0.7, 5.1) days, whereas our COVID-19 patient cohort required a median of 10.2 (3.74, 23.73) days. COVID-19 patients do not recover on a similar trajectory to other critical respiratory illnesses, including influenza, and allocation guidelines may need to extend their reassessment intervals. Determination of the appropriate length of time for a
trial of mechanical ventilation can be difficult since the physiologic trajectory of the disease—even with optimal treatment—may be unknown or variable. Too short a trial of ventilation and patients may have an inadequate length of time to demonstrate a clinical benefit. Short of objective evidence that a patient is failing therapy, premature reassessment that results in the removal of resources that might otherwise later benefit the patient may promote rapid cycling between patients irrespective of prognosis and worsen overall mortality. Too long between reassessments might lead to disproportionate resource utilization without optimizing overall survival.

Our results may signal that the recommended length of time for a ventilator time trial was too short to demonstrate improvement for COVID-19 patients. This is supported by the observation that ventilator reallocation would have occurred for over half of the simulated remaining patients on or after 2 days of mechanical ventilation, of which over one third were observed to survive to discharge (see Table 3). It is also corroborated by the 49.2% increase in patients who would survive to discharge if the second day of assessment of ventilator allocation was delayed to Day 5 (see Figure 3). This may suggest that the appropriate length of a time trial should be extended for COVID-19 patients compared to other typical causes of respiratory failure.

Potential Limitations

This study has several potential limitations. Although this simulation is not based on a fixed supply of ventilators and includes an unrealistic dynamic number of available ventilators, it provides an important analysis that best represents the true performance of commonly used SOFA cutoffs and reassessment intervals with respect to patient mortality. This design is crucial because guideline underperformance might be obscured under circumstances of low ventilator strain where the majority of patients are provided with a ventilator regardless of their eligibility. A true understanding of which patients are classified as ineligible for lifesaving resources and their chances of survival remains paramount to understanding how guidelines might perform with increasing resource strain. This cohort study also facilitates a unique opportunity to understand how many patients would have had their ventilator withheld (simulated) but would have otherwise survived if a ventilator was provided (because they were provided with a ventilator in the real world). Our simulation demonstrates the important concern that, according to the NYSVAG criteria studied, many patients who may have had their ventilators withdrawn would have subsequently survived. This concern would be mitigated, and NYSVAG indeed validated, if subsequent patients receiving reallocated ventilators had a higher rate of survival. We acknowledge that our study design cannot explicitly assess the mortality of subsequent patients receiving reallocated ventilators. However, our results suggest that patients ventilated for 5 or more days and selected to have their ventilator reallocated may have a higher chance of surviving to discharge with a ventilator (46.3-75.0%) than subsequent patients receiving their reallocated ventilator (43.4%) (see Table 3). This conjecture, if substantiated, may have significant implications as to how new patients should be triaged in the setting of existing ventilated patients. The survival of patients receiving reallocated ventilators must be explicitly studied before changes to existing protocols are proposed and adopted.

A simulation including a fixed number of available ventilators and patient throughput incorporating ventilator strain will produce different results and allow for the explicit study of patients receiving reallocated ventilators. In such a scenario, however, it...
Table 3. Numerical representation of a simulated application of NYSVAG to a cohort of critically ill COVID-19 patients

|          | Intubation (%) | Day 2 (%) | Day 5 (%) | Day 7 (%) | Day 9 (%) | Day 11 (%) |
|----------|----------------|-----------|-----------|-----------|-----------|------------|
|          | [95% CI]       | [95% CI]  |           | [95% CI]  |           |            |
| **Total N** | 884           | 678       | 226       | 56        | 6         | 2          |
| **Red**   | (54.1)        | (32.9)    | (11.1)    | (7.0, 15.2) | 7        | 2 (33.3)  |
|          | (50.8-57.4)   | (29.5-36.5) |           |           |           |            |
| Red who survived to discharge \(a\) | 221 | (46.2) | (12.5) | (6.2-23.6) | 2 | 0 |
|          | (41.8-50.7)   |           |           |           |           |            |
| **Yellow** | 285           | (7.4)     | (17.3)    | (12.3-22.2) | 39 | 1 (50.0)  |
|          | (32.2)        | (5.6-9.6) |           |           |           |            |
| Yellow who survived to discharge \(a\) | 110 | (38.6) | (29.2-33.4) | (18.7-31.1) | 24 | 1 (50.0)  |
|          | (33.1-44.4)   |           |           |           |           |            |
| **Blue \(b\)** | 121 | (13.7) | (11.6-16.1) | N/A | 404 | (66.7) | 2 (100) |
|          | (29.6-33.2)   |           |           |           |           |            |
| Blue who survived to discharge \(c\) | 31 | (25.6) | (18.7-34.1) | N/A | 136 | (75,0) | 1 (50.0) |
|          | (28.6-37.8)   |           |           |           |           |            |
| **ECMO** | 10 | (11) | 7 | (15) | 0 | 0 | 0 |
| **Exubated Survived** | 35 | (41) | 24 | (51) | 5 | (63) | 1 (100) |
| **Deceased** | 41 | (38) | 16 | (34) | 3 | (37) | 0 | 0 |

Numerical representation of Figure 2 depicting the simulated application of NYSVAG on a cohort of critically ill COVID-19 patients.

\(a\)Survival to hospital discharge is an observed outcome.

\(b\)Characterized as ineligible for a ventilator (Blue) and simulated for ventilator removal/withholding is a simulated outcome.

\(c\)Combined simulated-observed outcome; those who were classified as ineligible for a ventilator (Blue) in the simulation but were also observed to survive to hospital discharge when they were provided a ventilator in the real world.

Table 4. Etiology of patients triaged as Blue and ineligible for a ventilator during simulation

| Blue Reason for ventilator ineligibility | Intubation | Day 2 | Day 5 | Day 7 | Day 9 | Day 11 |
|----------------------------------------|------------|-------|-------|-------|-------|-------|
|                                        | Number survived to discharge/Total (%) [95% CI] |       |       |       |       |       |
| **SOFA > 11**                          | 31/121(25.6) | 21/110 | 1/13 | 0/0   | 0/0   | 0/0   |
|                                        | (18.7-34.1) | (19.1) | (7.7) | (0.0-35.4) |       |       |
| **SOFA 8-11 \(a\)**                   | N/A        | 72/204 | 25/61 | 1/7   | 0/1   | 0/0   |
|                                        | (35.3)     | (29.1-42.1) | (41.0) | (14.3) | (0)   |       |
|                                        | (29.5-63.3) |           | (29.5-53.5) | (7.6) |       |       |
| **SOFA ≤ 7 \(f\)**                    | N/A        | 43/90  | 49/88 | 33/42 | 3/3   | 1/2   |
|                                        | (47.8)     | (47.8) | (55.7) | (78.6) | (100) | (50)  |
|                                        | (37.8-58.0) |           | (45.3-65.6) | (63.9-88.5) |       |       |
|                                        | (37.8-58.0) |           | (45.3-65.6) | (63.9-88.5) |       |       |
| **Total**                             | 31/121(25.6) | 136/404 | 75/162 | 34/49 | 3/4   | 1/2   |
|                                        | (18.7-34.1) | (33.7) | (46.3) | (69.4) | (75)  | (50)  |

Etiology of patients classified as Blue and triaged as ineligible for a ventilator on the specified reassessment day of mechanical ventilation.

\(a\)See Figure 1 and Table 1 regarding specific criteria triaging patients as Blue or ineligible to receive or maintain a ventilator for the specific day reassessed.

\(f\)P value comparing SOFA > 11 of the same day.

\(f\)P value comparing SOFA 8-11 of the same day.
remains concerning that the majority of patients classified as Blue on or after 5 days of mechanical ventilation had a SOFA score of less than 7. Randomization may not maximize patient survival if it occurs among all Blue individuals and does not prioritize subcategories that are more likely to survive (see Table 4). A triage officer or committee may provide a more sensitive selection process; however, NYSVAG only permits randomization within a priority color. Further subcategorization of all patients classified as ineligible for a ventilator should be considered in resource allocation protocols. Subsequent studies incorporating a fixed number of available ventilators, real patient throughput, and the comparison of alternative triage strategies such as first-come first-served or a priority committee may provide a more sensitive selection process; however, they do not incorporate patient throughput or dynamic real-world surge strain.

We believe our results are broadly generalizable. While NYSVAG was designed for an influenza pandemic, the NYSVAG Q&A approve its application for a broader respiratory crisis. Although we analyzed limited aspects of NYSVAG, these elements are similar to several other resource allocation policies. NYSVAG is a sizeable cohort is generalizable to other COVID-19 patients as our SOFA score and PaO2/FiO2 at intubation and duration of mechanical ventilation are consistent with other reports. Our high mortality is consistent with local reports during the study period and likely related to the unprecedented surge and associated ICU strain that would be consistent in communities activating crisis standards of care. Our NYSVAG simulation results are additionality similar to a 210-patient mixed COVID-19 cohort from a comparable local institution. While all ventilated patients would participate in the same resource allocation policy, non-COVID-19 patients were excluded from this simulation because they were marginally present during our institutions’ surge.

There remain specific limitations related to the general dependence on SOFA scores for reallocation policies. While an initial report suggested that SOFA scores could predict mortality among COVID-19 patients, subsequent studies have not been as supportive. Despite such shortcomings, using an objective score to prioritize resource allocation with the intent of saving the most lives achieves impartiality, preserves fairness toward patients, promotes transparency with the community, maintains reproducibility between providers, eliminates the encroachment of bias or prejudices by decision-makers, and may reduce provider distress about ventilator allocation decisions. Such scores may require further augmentation to strive for equity and not worsen existing health disparities, or to better reflect community values. While many critically ill COVID-19 patients are at risk of multiple organ failure, some remain “single organ” dysfunction with respiratory failure, whereupon SOFA scores may not be the most accurate reflection of the severity of their illness.

Dependence on SOFA scores can be additionally problematic as COVID-19 patients often require prone positioning, which can complicate the interpretation of the oxygenation component, or heavy sedation or paralytics, which can interfere with the neurological assessment. In our simulation, GCS scores were normalized when they were not documented, which was overwhelmingly common and may be related to patients’ clinical contraindications for interruption of sedation or paralytics versus incomplete documentation. The frequency of missing data in Supplemental Table 2 underscores this point and may only be partially mitigated by using the mSOFA score. Our normalization of missing information underestimates a patient’s true SOFA score and therefore may underestimate the frequency of ventilator reallocation; 11.3% of our cohort was intubated without any SOFA information, possibly suggesting that first responders may need to make triage decisions with incomplete information.

**Conclusion**

States across the nation continue to battle against surges in the COVID-19 pandemic. Federal, state, and local governments should continue to study and develop their disaster preparedness
plans. Our results suggest that if NYS Ventilator Allocation Guidelines were implemented, patients might have their ventilator reallocated when they might otherwise survive. Further studies should determine whether subsequent patients receiving reallocated ventilators would have a higher survival than the original cohort before changes to the guidelines are enacted.

**Supplementary Material.** To view supplementary material for this article, please visit https://doi.org/10.1017/dmp.2022.154

**Acknowledgments.** We are grateful to Kelly Paluch for her statistical contributions.

**Author Contributions.** All authors contributed to all aspects except MEN, who was not involved in the study design.

The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States Government.

**Funding Statement.** This research is unfunded and approved by the NYU Grossman School of Medicine Office of Science and Research Institutional Review Board I2O-I01653. This project was presented as an abstract during the American Thoracic Society 2021.

**Conflict(s) of Interest.** The authors have no conflicts of interest.

**References**

1. WHO Director-General’s Opening Remarks at the Media Briefing on COVID-19. World Health Organization. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020. Published March 11, 2020. Accessed March 23, 2020.

2. Coronavirus Disease 2019 (COVID-19) Situation Report—51. World Health Organization. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10. Published March 11, 2020. Accessed January 13, 2021.

3. Jesse McKinley New York City Region is now an epicenter of the coronavirus pandemic. New York Times. https://www.nytimes.com/2020/03/22/nyregion/coronavirus-new-york-epicenter.html. Published March 22, 2020. Accessed January 13, 2021.

4. Coronavirus. Worldometer. https://www.worldometers.info/coronavirus/. Published date unknown. Accessed July 22, 2020.

5. COVID-19: Data. Department NYCH. https://www1.nyc.gov/site/doh/covid/covid-19-data.page#download. Published date unknown. Accessed July 22, 2020.

6. Cha A, Bernstein L, Sellers FSH, Harris S. Faced with a crush of patients, besieged NYC hospitals struggle with life-or-death decisions. The Washington Post. https://www.washingtonpost.com/health/2020/03/31/new-york-city-hospitals-coronavirus/. Published March 31, 2020. Accessed April 6, 2020.

7. Coronavirus: New York Forced to Redistribute Ventilators. BBC. https://www.bbc.com/news/world-us-canada-52148534. Published April 3, 2020. Accessed January 13, 2021.

8. Gutmann Koch V, Han SA. COVID in NYC: what New York did, and should have done. Am J Bioeth. 2020;20(7):153-155. doi: 10.1080/15265161.2020.1773750

9. Rosenthal BM, Goldstein J. N.Y. may need 18,000 ventilators very soon. It is far short of that. New York Times. https://www.nytimes.com/2020/03/17/nyregion/ny-coronavirus-ventilators.html?action=click&module=RelatedLinks&pgtype=Article. Published March 26, 2020. Accessed January 14, 2021.

10. Ventilator Allocation Guidelines. New York State Task Force on Life and the Law & New York State Department of Health. https://www.health.ny.gov/regulations/task_force/reports_publications/docs/ventilator_guidelines.pdf. Published November 2015. Accessed January 13, 2021.

11. White DB, Lo B. A framework for rationing ventilators and critical care beds during the COVID-19 pandemic. JAMA. 2020;323(18):1773-1774. doi: 10.1001/jama.2020.5046

12. Emanuel EJ, Persad G, Upshur R, et al. Fair allocation of scarce medical resources in the time of COVID-19. N Engl J Med. 2020;382(21):2049-2055. doi: 10.1056/NEJMsa2005114

13. Antonmaria AHM, Gibb TS, McGuire AL, et al. Ventilator triage policies during the COVID-19 pandemic at U.S. hospitals associated with members of the Association of Bioethics Program Directors. Ann Intern Med. 2020;173(3):188-194. doi: 10.7326/M20-1738

14. Fiest KM, Krewulak KD, Plotnikoff KM, et al. Allocation of intensive care resources during an infectious disease outbreak: a rapid review to inform practice. BMC Med. 2020;18(1):404. doi: 10.1186/s12916-020-01871-9

15. Piscitello GM, Kapania EM, Miller WD, et al. Variation in Ventilator Allocation Guidelines by US state during the coronavirus disease 2019 pandemic: a systematic review. JAMA Netw Open. 2020;3(6):e2012606. doi: 10.1001/jamanetworkopen.2020.12606

16. Fins JJ. Sunshine is the best disinfectant, especially during a pandemic. New York State Bar Association. https://nysba.org/sunshine-is-the-best-disinfectant—especially-during-a-pandemic/#_ftn30. Published June 1, 2020. Accessed April 3, 2022.

17. Alaska Activates the State’s Crisis Standards of Care for Multiple Health Care Facilities. Department of Health and Social Services SoA. https://health.alaska.gov/news/Documents/press/2021/DHSS_Press_Release_StateCSC_-20211002.pdf. Published October 2, 2021. Accessed July 28, 2022.

18. Idaho Activates Crisis Standards of Care in North Idaho Due to Surge in COVID-19 Patients Requiring Hospitalization. Welfare IDoH. https://healthandwelfare.idaho.gov/news/idaho-activates-crisis-standards-care-north-idahodue-surge-covid-19-patients-requiring-—text=patients%20requiring%20hospitalization—Idaho%20activates%20Crisis%20Standards%20for%20Care%20in%20the%20North%20Idaho%20due%20COVID-19%20patients%20requiring%20hospitalization&text=The%20Idaho%20Department%20of%20Health%2C%20the%20Idaho%20Crisis%20Standards%20for%20Healthcare%20Entities. Published September 7, 2021. Accessed July 28, 2022.

19. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 1991;100(6):1619-1636. doi: 10.1378/chest.100.6.1619

20. Wunsch H, Hill AD, Bosch N, et al. Comparison of 2 triage scoring guidelines for allocation of mechanical ventilators. JAMA Netw Open. 2020;3(12):e2029250. doi: 10.1001/jamanetworkopen.2020.29250

21. Kanter RK. Would triage predictors perform better than first-come, first-served in patient ventilator allocation? Chest. 2015;147(1):102-108. doi: 10.1378/chest.14-0584

22. Bhavani SV, Luo Y, Miller WD, Sanchez-Pinto LN, Han X, Mao C, Sandikci B, Peek ME, Coopersmith CM, Michelson KN, Parker WF. Simulation of Ventilator Allocation in Critically Ill Patients with COVID-19. Am J Respir Crit Care Med. 2021;204(10):1224-1227. doi: 10.1164/rccm.202106-1453LE

23. Ashana DC, Anesi GL, Liu VX, Escobar GJ, Chesley C, Eneanya ND, Weissman GE, Miller WD, Harhay MO, Halpern SD. Equitably Allocating Resources during Crises: Racial Differences in Mortality Prediction Models. Am J Respir Crit Care Med. 2021;204(2):178-186. doi: 10.1164/rccm.202012-4383OC

24. Gershengorn HB, Holt GE, Rezk A, et al. Assessment of disparities associated with a crisis standards of care resource allocation algorithm for patients in 2 US hospitals during the COVID-19 pandemic. JAMA Netw Open. 2021;4(3):e214149. doi: 10.1001/jamanetworkopen.2021.4149

25. Cleveland Manchanda EC, Sanky C, Appel JM. Crisis standards of care in the USA: a systematic review and implications for equity amidst COVID-19. J Racial Ethn Health Disparities. 2020;1-13. doi: 10.1007/s40615-020-00840-5

26. Cleveland Manchanda E, Couillard C, Sivashanker K. Inequity in crisis standards of care. N Engl J Med. 2020;383(4):e16. doi: 10.1056/NEJMp2011359

27. Frequently Asked Questions: New York State Task Force on Life and the Law and the New York State Department of Health’s Ventilator Allocation Guidelines. https://www.health.ny.gov/regulations/task_force/
28. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet.* 2020;395(10239):1763-1770. doi: 10.1016/s0140-6736(20)31189-2

29. Ziehr DR, Alladina J, Petri CR, et al. Respiratory pathophysiology of mechanically ventilated patients with COVID-19: a cohort study. *Am J Respir Crit Care Med.* 2020;201(12):1560-1564. doi: 10.1164/rccm.202004-1163LE

30. Ling L, So C, Shum HP, et al. Critically ill patients with COVID-19 in Hong Kong: a multicentre retrospective observational cohort study. *Crit Care Resusc.* 2020;22(2):119-125.

31. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. *Lancet Respir Med.* 2020;8(5):475-481. doi: 10.1016/s2213-2600(20)30079-5

32. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. *JAMA.* 2020;323(16):1574-1581. doi: 10.1001/jama.2020.5394

33. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ.* 2020;369:m1966. doi: 10.1136/bmj.m1966

34. Toth AT, Tatem KS, Hosseinipour N, et al. Surge and mortality in ICUs in New York City’s public healthcare system. *Crit Care Med.* 2021;49:1439-1450. doi: 10.1097/CCM.0000000000004972

35. Santos HT, Levy BM, Gong MN, et al. How useful are Sequential Organ Failure Assessment (SOFA) score-based ventilator triage guidelines during the COVID-19 pandemic? TP11. TP011 USE OF HEALTH SERVICES AND MEDICAL EDUCATION RESEARCH TO EVALUATE THE EFFECT OF COVID-19:A1494-A94.

36. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet.* 2020;395(10229):1054-1062. doi: 10.1016/s2213-2600(20)30566-3

37. Raschke RA, Agarwal S, Rangan P, et al. Discriminant accuracy of the SOFA score for determining the probable mortality of patients with COVID-19 pneumonia requiring mechanical ventilation. *JAMA.* 2021;325:1469-1470. doi: 10.1001/jama.2021.1545

38. Shahpouri R, Stelfox HT, Doig CJ, et al. Sequential Organ Failure Assessment in H1N1 pandemic planning. *Crit Care Med.* 2011;39(4):827-832. doi: 10.1097/CCM.0b013e318206d548

39. White DB, Lo B. Mitigating inequities and saving lives with ICU triage during the COVID-19 pandemic. *Am J Respir Crit Care Med.* 2021;203(3):287-295. doi: 10.1164/rccm.202010-3809CP

40. Biddison ELD, Gwon HS, Schoch-Spana M, et al. Scarce resource allocation during disasters: a mixed-method community engagement study. *Chest.* 2018;153(1):187-195. doi: 10.1016/j.chest.2017.08.001